Cytek Biosciences
Cytek Biosciences' revenue rose 0.5% to $202 million in fiscal 2025. Its operating margin was −20.0%, down from −10.2% a year earlier. Free cash flow was −$9 million, against $22 million a year earlier. It paid out $15 million in dividends and buybacks. The diluted share count fell 2.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cytek Biosciences does
Cytek Biosciences makes instruments that analyze individual cells, used by scientists in drug research, universities and clinical labs. Its technology, called Full Spectrum Profiling, detects the full range of light given off by fluorescent tags on cells, using several lasers. Cytek says this lets researchers tag up to 50 markers in a single tube.
Its products are the Cytek Aurora, Northern Lights and Aurora Evo cell analyzers and the Aurora CS cell sorter, which separates cells of a chosen type. Each runs on Cytek's SpectroFlo software. It also sells the chemical reagents used with the machines and offers service contracts. It has sold instruments since mid-2017 to drug and biotech companies, academic research centers and contract research organizations, which run studies for others, in many countries.
Cytek earns money from selling instruments, and from reagents and services that customers buy to keep using them. It competes with makers of conventional flow cytometry, a standard cell analysis method, and of other cell analysis tools. It says more than 3,500 peer-reviewed articles have been published about research that used its products.
Its biggest risks, as it describes them
- Depending on a small number of product lines, mainly its Aurora, Northern Lights and Aurora CS systems.
- A limited operating history, which makes its future performance hard to predict.
- Relying on single or sole suppliers for certain parts and materials.
- Tariffs, trade policies and export controls that could cut demand or raise costs.
- Risks of operating in many countries, and the difficulty of forecasting demand and managing inventory.
Income statement
From fiscal 2020 to 2022, earnings per share fell 55.3% a year and net income 64.1% a year, as new shares raised the share count by 325% and diluted each share's earnings. Cytek Biosciences then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 365 | 297 | 167 | 99 | 91 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 5.3x | −0.7x | −13.4x | −3.9x | −85.2x |
| Current ratio | 13.0x | 9.3x | 7.0x | 5.9x | 5.0x |
| Quick ratio | 12.0x | 8.3x | 5.9x | 5.2x | 4.4x |
Cash flow
Projections
Project Cytek Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Cytek Biosciences says to expect
- Full year 2026: revenue
Cytek Biosciences is maintaining the midpoint of its revenue outlook for the full year 2026 and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates.
Insider trades
No officer, director or 10% owner of Cytek Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 6,414.5% | 14.8% | −3.8% |
| Altman Z'' | 7.96 | 7.82 | 6.15 |
| Accruals ratio | −3.4% | −6.3% | −12.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Cytek Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | Compare |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| Mesa Laboratories | FY26 | 3.4% | 7.4% | 15.9% | 4.8% | 1.0x | 8 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1 | 2 | 3 | 193 | 200 | 202 |
| Revenue growth | — | 207.2% | 35.9% | 6,414.2% | 3.9% | 0.5% |
| Gross profit | 52 | 79 | 101 | 109 | 111 | 104 |
| Research and development | 14 | 24 | 35 | 44 | 39 | 36 |
| Operating income | 14 | 9 | −2 | −28 | −20 | −40 |
| Net income | 19 | 3 | 2 | −12 | −6 | −66 |
| Diluted EPS (US$) | 0.10 | 0.00 | 0.02 | −0.09 | −0.05 | −0.52 |
| Diluted shares (millions) | 33 | 82 | 139 | 135 | 131 | 128 |
| Cash flow | ||||||
| Cash from operations | 15 | 5 | −12 | 5 | 25 | −5 |
| Capital expenditure | 2 | 4 | 10 | 5 | 4 | 4 |
| Free cash flow | 14 | 0 | −22 | 1 | 22 | −9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 44 | 22 | 15 |
| Acquisitions | 0 | 17 | 0 | 45 | 0 | 0 |
| Stock-based compensation | 1 | 7 | 17 | 22 | 27 | 25 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 165 | 365 | 297 | 167 | 99 | 91 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 220 | 463 | 520 | 494 | 500 | 462 |
| Total liabilities | 42 | 58 | 94 | 101 | 104 | 120 |
| Shareholders' equity | −16 | 405 | 426 | 393 | 396 | 342 |
| Margins and ratios | ||||||
| Gross margin | 7,283.1% | 3,628.8% | 3,407.8% | 56.7% | 55.4% | 51.8% |
| Operating margin | 1,923.8% | 419.9% | −60.9% | −14.4% | −10.2% | −20.0% |
| Net margin | 2,733.9% | 138.8% | 83.8% | −6.3% | −3.0% | −33.0% |
| Free cash flow margin | 1,916.8% | 12.2% | −741.8% | 0.3% | 10.9% | −4.3% |
| Rule of 40 (growth + FCF margin) | — | 219.4% | −705.9% | 6,414.5% | 14.8% | −3.8% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | 1.6% | 0.6% | −3.0% | −1.5% | −18.1% |
| Return on assets | — | 0.9% | 0.5% | −2.4% | −1.2% | −13.8% |
| Net debt to EBITDA | — | — | — | — | — | — |